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Abstract
Objective
To raise awareness of complement factor I (CFI) deficiency as a potentially treatable cause of
severe cerebral inflammation.
Methods
Case report with neuroradiology, neuropathology, and functional data describing the mutation
with review of literature.
Results
We present a case of acute, fulminant, destructive cerebral edema in a previously well 11-year-
old, demonstrating massive activation of complement pathways on neuropathology and
compound heterozygote status for 2 pathogenic mutations in CFI which result in normal levels
but completely abrogate function.
Conclusions
Our case adds to a very small number of extant reports of this phenomenon associated with
a spectrum of inflammatory histopathologies including hemorrhagic leukoencephalopathy
and clinical presentations resembling severe acute disseminated encephalomyelitis. CFI
deficiency can result in uncontrolled activation of the complement pathways in the brain
resulting in devastating cerebral inflammation. The deficit is latent, but the catastrophic
dysregulation of the complement system may be the result of a C3 acute phase response.
Diagnoses to date have been retrospective. Diagnosis requires a high index of suspicion and
clinician awareness of the limitations of first-line clinical tests of complement activity and
activation. Simple measurement of circulating CFI levels, as here, may fail to diagnose
functional deficiency with absent CFI activity. These diagnostic challenges may mean that the
CFI deficiency is being systematically under-recognized as a cause of fulminant cerebral
inflammation. Complement inhibitory therapies (such as eculizumab) offer new potential
treatment, underlining the importance of prompt recognition, and real-time whole exome
sequencing may play an important future role.
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We report a case of life-threatening, nonhemorrhagic fulmi-
nant CNS inflammation, radiologically resembling acute dis-
seminated encephalomyelitis (ADEM), in association with
complete complement factor I (CFI) functional deficiency. A
very few such cases have been reported to date, all identified
retrospectively via whole exome sequencing (WES) and/or
known family history. Complement inhibition (e.g., with
eculizumab) represents a potential therapeutic option in this
otherwise devastating illness but would require prompt rec-
ognition. The index case had a functional CFI deficiency (with
normal serum CFI levels), emphasizing that simple serum
complement assays will not exclude CFI deficiency and the
challenge of timely diagnosis. CFI deficiency may be an
under-recognized cause of encephalitis of “presumed viral” or
unknown etiology. Improved outcome will require greater
awareness of the condition and a high index of suspicion.
Case
An 11-year-old Caucasian girl presented with a 5 days history
of fever, headache, and vomiting. She had no significant
medical history and no recent foreign travel. Initial GCS was
14 of 15 but rapidly fell to 8. She was intubated and ventilated.
Temperature on admission was 37.6°C. White blood cell
count was 14.3 mm−3, with 90% neutrophils with an eryth-
rocyte sedimentation rate of 103 mm—/h. C-reactive protein
was 201 mg/L.
Initial CT of the head showed no bleed or mass. Initial MRI
(figure 1) demonstrated bilateral, asymmetrical, predominantly
white matter edema with posterior corpus callosal changes;
some gray matter involvement of thalami; and patchy en-
hancement postcontrast. There was no restricted diffusion. She
developed rapidly progressive, life-threatening cerebral edema
requiring an external ventricular drain followed by bifrontal
decompressive craniectomy at which point a superficial cortical
brain biopsy was obtained. There were no significant light
microscopic abnormalities. Immunohistochemical studies
showed no evidence of a demyelinating process with fewT cells
in the tissue. There was marked astrogliosis (indicated by glial
fibrillary acidic protein staining, figure 2E) and microgliosis
(ionized calcium binding adapter molecule 1 staining, figure
2F) accompanied by deposition of C3b/iC3b (figure 2G) and
terminal complement complex (figure 2F), both of which ap-
pear neuronal in location.
She was treated with ceftriaxone and aciclovir for presumed
meningoencephalitis, high-dose methylprednisolone (1 g daily
for 5 days), followed by an extended high-dose enteral
prednisolone taper; plasmapheresis with human albumin so-
lution and fresh frozen plasma (FFP) (days 5–15 inclusive);
and rituximab (total 1125 mg/m2 in 2 doses, days 6 and 21,
because of concern about possible washout of the first dose
with plasmapheresis) for a working diagnosis of severe ADEM.
There was little obvious benefit. The severely elevated in-
tracranial pressure began to settle around day 6. By day 14,
some withdrawal from painful stimuli was noted. Blood and
CSF cultures were negative for primary bacterial infection. CSF
virology was negative for herpes simplex, varicella, Enterovirus,
and Parechovirus by PCR. An initial CSF sample was heavily
blood-stained with protein 0.81g/L and 30,000 erythrocytes/
mm3 but no excess of CSF leukocytes. Subsequent CSF sam-
ples showed no CSF leukocytes. Antibodies to myelin-
oligodendrocyte glycoprotein, aquaporin 4, glycine receptors,
voltage-gated potassium channel-related proteins, and NMDA
receptors were all negative. Immunoglobulin levels at pre-
sentation were normal.
Retrospectively, a neuroinflammatory gene panel identified
2 pathogenic CFI variants (c.1019T>C p.(Ile340Thr) and
c.1555 G>A p.(Asp519Asn). Subsequent Sanger sequencing of
the proband and parents confirmed compound heterozygote
status. Subsequent complement assays were performed
8months after presentation. C3 andC4were within the normal
range (0.72 [normal range (NR) 0.68–1.80] and 0.35 [NR
0.18–0.6] g/L, respectively). CFI and complement factor H
(CFH) were within the normal range (29 mg/L [NR 21–40]
and 0.59 [NR 0.56–0.94] g/L, respectively). There wasmarked
activation of the alternative pathway (AP) with markedly low
complement factor B (CFB; 49 mg/L: NR > 186 mg/L) and
absent AP haemolytic activity (AP100).
Nearly 2 years from presentation, the patient has been left
with a profound neurologic deficit with tetraplegia, although
she can write slowly with specialist aids indicating relative
cognitive preservation. A seizure disorder is well controlled
with levetiracetam. She has commenced penicillin prophylaxis
and has been immunized against capsulated organisms in light
of the absent AP activity. Follow-up imaging at 6 months
showed severe widespread atrophy with no new signal ab-
normality (supplemental data figure 2, links.lww.com/NXI/
A208).
Discussion
We describe a patient with compound heterozygote, complete
CFI deficiency, with a nonclassic, neurologic presentation. CFI
is a complement regulatory protein that inactivates all pathways
Glossary
ADEM = acute disseminated encephalomyelitis; AHLE = acute hemorrhagic leukoencephalopathy; aHUS = atypical
haemolytic uraemic syndrome; AP= alternative pathway; CFB = complement factor B; CFH = complement factor H; CFI =
complement factor I; FFp = fresh frozen plasma; WES = whole exome sequencing.
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of the complement system by cleaving the α9-chains of C3b and
C4b (figure 3). Complete CFI deficiency is believed to be rare
and, as would be predicted, has mainly been reported in as-
sociation with primary infection (including CNS infection)
with encapsulated microorganisms.1 Heterozygote status for
CFI deficiency has been associated with atypical hemolytic
uraemic syndrome (aHUS) (i.e., not associated withEscherichia
coli gastroenteritis)2 and age-related macular degeneration.3
CFI-mediated complement regulation may also be important
in the progression of early phase Alzheimer disease.4
Figure 1 Representative MR images
Representative neuroradiologic images. (A–C) Acute imaging
on day 2 of admission shows bilateral, asymmetrical, pre-
dominantly white matter changes, although some gray
matter involvement of thalami is also seen. Patchy en-
hancement postcontrast and mass effect and effacement of
the sulci. Diffusion-weighted imaging (not shown) did not
indicate any area of restricted diffusion. (D) Approximately 1
month later showing postcraniectomy changes and sub-
stantial resolution of the acute inflammation. (A, B, and D =
T2-weighted; C = postcontrast T1-weighted).
Figure 2 Immunohistochemistry
Immunohistochemistry of parietal cortical sample obtained at the time of craniectomy demonstrate reactive astrogliosis, microgliosis, and complement
deposition. Top row (A–D) indicates controls (secondary antibody only). Bottom row (E–H) indicates antibody staining. A and E, Reactive astrocytemarker glial
fibrillary acidic protein. B and F, Pan-microglial marker ionized calcium binding adapter molecule 1. C and G, In-house anti-C3b/iC3b monoclonal antibody
C3/30. D and H, Anti-C9 neoantigen-specific monoclonal antibody B7 (membrane attack complex). Scale bars = 50 μm.
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A report of 2 unrelated children of Filipino descent5 and a recent
adult brief report6 describe acute hemorrhagic leukoencephal-
opathy (AHLE) in association with complete CFI deficiency.
All had infrequently recurrent episodes, at intervals of several
years, commencing in the second decade of life. Radiologically,
our case resembles case B in Shields et al.,6 but appears uniquely
severely affected among cases reported to date.
We speculate that the basis for such infrequent, fulminant
presentations may be that the CFI deficiency causes chronic
AP activation limited only by depletion of its substrate C3. C3
is an acute phase protein. and stressors such as viral infection
may result in a rapid surge in C3 production, freeing the
previously substrate-limited AP and resulting in a catastrophic
runaway that overwhelms downstream complement regu-
lators (which are in any case poorly expressed in the brain). In
this context, one could hypothesize that our use of plasma-
pheresis with FFP may have been deleterious because of de-
livery of exogenous (functional) factor I and C3, facilitating
proinflammatory conversion of C3b to iC3b (figure 3), al-
though no clinical deterioration was detectable at the time.
We were not able to identify an infective trigger in our case
although she had been pyrexial before admission.
Our case had no radiologic or pathologic evidence of hemor-
rhage, suggesting an AHLE phenotype is not consistent and that
neuroradiologic appearances can resemble acute demyelination.
Complement activation is a recognized pathophysiologic mech-
anism in neuromyelitis optica and related disorders,7,8 sug-
gesting a basis for similar radiologic appearances.
Improved outcomes are likely to depend on prompt recognition
of the CFI deficiency to administer anticomplement drugs. This
case highlights several diagnostic pitfalls. The patient’s I340T and
D519N variants have been reported (as heterozygotes) in as-
sociation with aHUS (see supplemental data, links.lww.com/
NXI/A208). In both instances, absolute levels of CFI were
normal; however, functional analysis demonstrated almost
complete abrogation of enzymatic activity.9 Thus, unlike pre-
vious cases,5 our patient was in the highly unusual situation of
having antigenically normal CFI levels but severely deficient CFI
activity from both mutant alleles. In addition, the unexpected
finding of normal serum C3 level in the serum reflects the fact
that routine clinical assays may also detect other forms of C3, in
this setting,most likelyC3b. Themost reliable routinely clinically
available diagnostic clue in this situation is the markedly reduced
CFB level that reflects excessive CFB consumption because of
a lack of inhibition of the amplification loop (figure 3).
In keeping with other reports,5 our patient showed no response
to plasma exchange or rituximab, although case B in Shields et al.6
did show a response to methylprednisolone. Broderick et al.5 saw
modest benefits coinciding with anakinra use. Eculizumab is the
only currently available complement inhibitor. It is a monoclonal
antibody that specifically binds to C5 and blocks its cleavage,
preventing formation of the membrane attack complex and C5a
release. There is growing interest in the potential of eculizumab in
severe autoimmune demyelinating neuroinflammatory disease,
particularly anti-aquaporin 4-mediated neuromyelitis optica.8 In
future cases of unexplained ADEM or AHLE, we suggest that
clinicians investigate the presence of a potential complement
Figure 3 Complement biology
Highly simplified cartoon of complement amplification loop pathways indicating (left, normal healthy condition) how C3/C3b levels reflect an equilibrium
between 2 cycles: one of C3 cleavage to form C3b that interacts with factor B, which is then cleaved by factor D to form the C3 convertase (C3bBb) to cleave
more C3 and a CFI-dependent C3b inactivation cycle. In factor I deficiency (right), a lack of C3b inactivation causes uncontrolled accumulation of C3b, rapid
consumption of C3, and activation of the downstream terminal pathway. Excessive activation of the C3b amplification loop can be inferred from CFB levels
that are markedly reduced because of consumption. CFB = complement factor B; CFI = complement factor I.
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regulation defect via extended complement assays (including
complement function, activation products, and levels of CFI,
CFH, and CFB). Real-time WES10 may also play an important
future role in diagnosis. The identification of complement regu-
lator defects would provide a biological rational for the use of
eculizumab and the next wave of 2nd generation complement
inhibitory therapies.
Deidentified clinical data will be made available on appro-
priate request to the corresponding author.
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